Summary:
DMI Research is conducting a phase 3 multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of bococizumab (pf-04950615),
in reducing the occurrence of major cardiovascular events in high risk subjects.
Qualified Participants Must:
• Be 18 years of age or older
•
Be at high or very high risk of incurring a CVD event or has had a CVD event occur in the last 5 years
•
Be treated with one of the highly effective statins required by the protocol at the specified daily doses for > 6 weeks prior to the screening visit
Qualified Participants May Receive:
Compensation for time and travel if you qualify for the study.